A long-acting interleukin-7, rhil-7-hyfc, enhances car t cell expansion, persistence, and anti-tumor activity

HIGHLIGHTS

• who: Miriam Y. Kim from the Department Washington University have published the paper: A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
• what: The authors show that rhIL-7-hyFc dramatically enhances CAR T_cell expansion, persistence, and anti-tumor efficacy, resulting in significantly prolonged survival of mice in CD19+ lymphoma and CD33+ leukemia xenograft models treated with human CAR T_cells, and in immunocompetent mice bearing CD19+ tumors treated with murine CAR T_cells.
• how: In this experiment the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.